Test your compounds and therapies on real human tissue
Human tissue. Human answers.
StemX Bio produces iPSC-derived 3D microtissues that replicate native tissue structure and function. Data that translates, from the plate to the clinic.
of drugs entering clinical trials fail
of therapies tested in animals reach regulatory approval
Ineichen et al., PLOS Biology, 2024
Current models don't reflect human biology.
We built one that does.
3D human tissue models built from stem cells
We differentiate human iPSCs into 3D pancreatic microtissues that contain all key endocrine cell types. These tissues respond to glucose, secrete insulin, and behave like real human pancreatic islets.
The result: preclinical data that actually translates to human outcomes. No animal models. No flat cell lines. Just human biology in a plate.
Elena Naumovska (CSO) and Jane Spirkoski (CEO) with a 384-well microtissue plate in our lab, Leiden.
What makes our microtissues different
Human-relevant
Derived from human iPSCs. No animal models. All key endocrine and exocrine cell types. Results that translate to human outcomes.
Standardized
Chemically defined, quality-controlled lots. Low batch-to-batch variability. Reproducible results you can build a program on.
Automation-ready
Compatible with multiple 96-well plate formats. 384-well in development. Designed for robotic handling and high-content screening.
How a pilot study works
Consult
Tell us about your compound and targets. We design the study together.
Design
We define the protocol: cell type, assay conditions, controls, and endpoints.
Execute
Our lab produces the microtissues, runs the assays, and collects the data.
Deliver
You receive a full report with raw data, analysis, and next-step recommendations.
active collaborations
years combined expertise
tissue types in development
Our partners and collaborators
Elena Naumovska (CSO) invented our microtissue technology. Her PhD and post-doc in 3D tissue engineering and iPSC differentiation are the foundation of everything we make. Jane Spirkoski (CEO) brings nine years of pharmaceutical development from Janssen, Batavia Biosciences, and Mymetics.
Together they lead a team of seven in Leiden, The Netherlands. We work with clients long-term, not just for one study.
Meet the full teamLatest from StemX Bio
February 12, 2026
Springboard pitch at DCVA & RegMed XB
StemX Bio joined the DCVA & RegMed XB Community Event in Utrecht, pitching to the Dutch regenerative medicine community.
Read more →February 6, 2026
Lab expansion for screening service
Added confocal imaging and flow cytometry capabilities to support deeper, multi-parameter readouts for client programs.
Read more →February 2026
KvW Innovation Voucher awarded
StemX Bio awarded the KvW Innovation Voucher under Leiden Bio Science Park, supporting our participation in the unlock_ incubation program.
Read more →Start a pilot with us.
Tell us about your compound, vector, or research question. We will tell you whether our platform is a fit and how we would approach the study.